Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

inances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 /PRNewswire/ ... health care services and one of the largest ... that its parent company and sole stockholder, Capella ... Medical Properties Trust, Inc. ("MPT") (NYSE: MPW ... cash.  The transaction is expected to be finalized ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
(Date:7/27/2015)... ... July 27, 2015 , ... This is a professional ... a basic overview of the industry including definitions, classifications, applications and industry chain ... trends, competitive landscape analysis, and key regions development status. Development policies and plans ...
Breaking Biology Technology:Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Quest PharmaTech Closes $1,000,000 Private Placement 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
... 7 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... Corporate Development of BioMarin, will present a company update at ... 14, 2009 at 10:40 a.m. CT. Interested parties may ... the investor section of the BioMarin website, www.BMRN.com ...
... deCODE genetics, Inc.,(Nasdaq: DCGN ) today announced that it ... release to be issued on Monday, May 11, after,the close ... a live webcast of,its conference call to discuss these results ... Daylight Time/ 12pm GMT/1pm British Summer,Time. , ...
... (NYSE: CVD ) announced that it has ... McCartney currently serves as chairman of the board of ... and supply chain solutions. He was formerly president ... multibillion dollar provider of information access technologies. He was ...
Cached Biology Technology:BioMarin to Present at the Baird Growth Stock Conference 2deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results 2Covance Elects John McCartney to Company's Board of Directors 2
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... crystals measuring just a few billionths of a meter ... for a wide range of applications. Nanocrystals could be ... or the glowing pixels on high-resolution display screens. They ... The size of a semiconductor nanocrystal determines its electrical ...
... Researchers at King,s College London, in collaboration with ... have succeeded in mapping how light behaves in ... butterfly wings. Scientists have broken the limit of ... fundamental insight into how light and matter interact, ...
... ( www.medboxinc.com ) Medbox, Inc. released their ... over $820,000 for the three-month period ending June 30. Cash ... year, and receivables jumped to an impressive 1.1 million. ... and the sales of their proprietary prescription medicine dispensing systems. ...
Cached Biology News:Patterning defect-free nanocrystal films with nanometer resolution 2Patterning defect-free nanocrystal films with nanometer resolution 3Scientists shed light on glowing materials 2Scientists shed light on glowing materials 3Medbox, Inc. Releases 2nd Quarter Financials 2
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
... (VMAT2). An antibody made to the C-terminal ... ~55 kDa in postnuclear supernatants of CHO ... type cells (2). Some additional bands, both ... detected and remain unaffected by the inclusion ...
Biology Products: